Influenza & Emerging Infectious Diseases (IEID)

BARDA uses a comprehensive portfolio approach to develop and acquire a broad array of medical countermeasures for pandemic influenza, including vaccines, therapeutics, diagnostics, and non-pharmaceutical countermeasures and to build and sustain their domestic manufacturing infrastructure.

Learn More

Pharmaceutical Countermeasures & Infrastructure (PCI)

Maintains manufacturing capabilities to respond to any pandemic or public health emergency.

Learn More

ADVANCING INNOVATION WITH BARDA

Government Can Drive Innovation! At BARDA We Seek Innovation in Science…. and in the way we do business! BARDA has a long history of designing and launching innovative programs, to accelerate innovative ideas and deliver promising countermeasures to protect Americans.

Learn More

Detection, Diagnostics, And Devices Infrastructure

Rapid response to CBRN, pandemic influenza and emerging infectious disease threats requires a robust investment in diagnostics and devices across the spectrum of advanced research and development, stockpiling and domestic manufacturing capacity expansion.

Learn More

Division of Contract Management and Acquisition (CMA)

CMA is a dynamic organization that provides flexible, consistent, and innovative acquisition solutions in support of necessary medical countermeasures. Through its commitment to excellence in contracting, ethics and transparency, and its focus on collaboration with internal and external partners, CMA strives to enhance the U.S. government’s capability to respond quickly to both known and emerging public health threats.

Learn More

Division of Research, Innovation & Ventures (DRIVe)

DRIVe's mission is to accelerate the development and availability of transformative technologies and approaches to protect Americans from health security threats. DRIVe pushes innovation boundaries to tackle the biggest health security challenges while seeking new ideas and new approaches to prevent and protect against health security threats.

Learn More

Division of Clinical Development (DCD)

DCD provides clinical development and operations expertise to BARDA programs that support the development of MCMs. DCD also manages the Clinical Studies Network (CSN) that develops clinical protocols for evaluation and testing in FDA-regulated trials; provides for long-term storage services for investigational product retains and clinical and nonclinical specimens to support future assay development and a statistical and data coordinating center for harmonization of data across BARDA projects and the archival of trial master file documents.

Learn More

Regulatory and Quality Affairs (RQA)

Ensures the development and availability of safe and effective medical countermeasures (MCMs) in compliance with relevant and current laws, regulations, and guidelines. Demonstrates regulatory excellence by providing technical expertise and by fostering the development of innovative regulatory and policy approaches on MCM-related topics.

Learn More

Division of Nonclinical Development (DNCD)

Providing nonclinical development support for the evaluation and licensure of medical countermeasures (MCMs).

Learn More

Chemical, Biological, Radiological & Nuclear (CBRN)

The Pandemic and All Hazards Preparedness Act (PAHPA) established BARDA as the focal point within HHS for the advanced development of and acquisition of medical countermeasures to protect the American civilian population against CBRN and naturally occurring public health threats.

Learn More